FRA:9VC - NL0015000DX5 - Common Stock
The current stock price of 9VC.DE is 3.837 EUR. In the past month the price increased by 6.7%. In the past year, price increased by 159.43%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY.DE | ELI LILLY & CO | 45.04 | 588.70B | ||
1LLY.MI | ELI LILLY & CO | 44.97 | 587.85B | ||
ZEG.DE | ASTRAZENECA PLC | 18.48 | 432.52B | ||
JNJ.DE | JOHNSON & JOHNSON | 17.85 | 367.61B | ||
1JNJ.MI | JOHNSON & JOHNSON | 17.65 | 365.97B | ||
RHO.DE | ROCHE HOLDING AG-BR | 14.75 | 250.06B | ||
NOT.DE | NOVARTIS AG-REG | 14.84 | 214.61B | ||
NOV.DE | NOVO NORDISK A/S-B | 14.08 | 209.02B | ||
SAN.PA | SANOFI | 10.53 | 193.90B | ||
SNW.DE | SANOFI | 10.53 | 193.90B | ||
1SAN.MI | SANOFI | 10.52 | 193.75B | ||
6MK.DE | MERCK & CO. INC. | 10.96 | 180.09B |
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
ATAI LIFE SCIENCES NV
Prof. J.H.Bavincklaan 7
Amstelveen NOORD-HOLLAND NL
Employees: 54
Phone: 31207932536
The current stock price of 9VC.DE is 3.837 EUR. The price increased by 3.45% in the last trading session.
The exchange symbol of ATAI LIFE SCIENCES NV is 9VC and it is listed on the Deutsche Boerse Ag exchange.
9VC.DE stock is listed on the Deutsche Boerse Ag exchange.
15 analysts have analysed 9VC.DE and the average price target is 9.79 EUR. This implies a price increase of 155.05% is expected in the next year compared to the current price of 3.837. Check the ATAI LIFE SCIENCES NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ATAI LIFE SCIENCES NV (9VC.DE) has a market capitalization of 822.42M EUR. This makes 9VC.DE a Small Cap stock.
ATAI LIFE SCIENCES NV (9VC.DE) currently has 54 employees.
ATAI LIFE SCIENCES NV (9VC.DE) has a support level at 3.71. Check the full technical report for a detailed analysis of 9VC.DE support and resistance levels.
The Revenue of ATAI LIFE SCIENCES NV (9VC.DE) is expected to grow by 314.74% in the next year. Check the estimates tab for more information on the 9VC.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
9VC.DE does not pay a dividend.
ATAI LIFE SCIENCES NV (9VC.DE) will report earnings on 2025-11-11, before the market open.
ATAI LIFE SCIENCES NV (9VC.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.59).
ChartMill assigns a technical rating of 10 / 10 to 9VC.DE. When comparing the yearly performance of all stocks, 9VC.DE is one of the better performing stocks in the market, outperforming 98.96% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to 9VC.DE. 9VC.DE has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months 9VC.DE reported a non-GAAP Earnings per Share(EPS) of -0.59. The EPS decreased by -72.5% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -78.89% | ||
ROE | -103.85% | ||
Debt/Equity | 0 |
15 analysts have analysed 9VC.DE and the average price target is 9.79 EUR. This implies a price increase of 155.05% is expected in the next year compared to the current price of 3.837.
For the next year, analysts expect an EPS growth of 48.51% and a revenue growth 314.74% for 9VC.DE